全血豚で表されるコーディングおよび非コーディングの RNA クラスの識別

Executive Industry Relevance

This protocol enables simultaneous analysis of coding and non-coding RNA from a single whole blood sample, reducing sample requirements and improving data consistency for host-pathogen interaction studies. By capturing mRNA, ncRNA, and viral RNA expression in parallel, it supports more efficient target validation and mechanistic de-risking in early discovery. The approach addresses a key bottleneck in transcriptomic workflows where separate sample preparations limit multi-omic insights and increase resource use.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by linking ncRNA regulatory networks to mRNA expression changes in immune response pathways.
• Operational Value: Reduces biological variability and sample processing time by deriving both coding and non-coding RNA profiles from one porcine whole blood aliquot.
• Predictive Value: Improves confidence in target selection by capturing coordinated expression of miRNAs, piRNAs, and mRNAs that influence host-amino acid response and pathogen susceptibility.

Screening & Assay Development

• Scientific Value: Generates globin-depleted RNA with RIN values ranging from 6.3 to 9.2, enabling high-quality library preparation for downstream sequencing applications.
• Operational Value: Eliminates the need for size selection, increasing recovery of methylated and small RNA species that are often lost in standard protocols.
• Assay Readiness: Produces consistent electropherogram profiles with mRNA peaks at ~280 bp and ncRNA peaks at 100–400 bp, supporting reproducible library quantification and normalization.

Translational & Preclinical Research

• Scientific Value: Facilitates study of ncRNA-mediated regulation in infection models, where miRNA and piRNA expression changes correlate with pathophysiological pathways.
• Translational Continuity: Supports biomarker discovery by enabling paired analysis of coding and non-coding RNA from the same animal, reducing inter-sample variability in longitudinal studies.
• Mechanistic De-risking: Allows researchers to assess whether observed mRNA changes are driven by transcriptional regulation or post-transcriptional ncRNA activity before advancing to functional validation.

Pipeline & Workflow Integration

The method fits within the discovery continuum from hypothesis generation through lead optimization, particularly in immunology and infectious disease programs where host response profiling informs target selection.

• Discovery Biology: Supports pathway clarification by enabling concurrent measurement of mRNA expression and regulatory ncRNA species that modulate immune cell function.
• Screening: Delivers standardized, globin-reduced RNA suitable for NGS library prep, improving reproducibility across compound or pathogen challenge screens.
• Analytics: Provides quantitative RNA integrity and size distribution data (RIN 6.3–9.2, defined peaks) that inform sequencing depth and batch correction strategies.
• Translational Research: Enables correlation of ncRNA expression with mRNA signatures in disease-relevant systems, supporting early biomarker linkage.
• Enterprise Reuse: Establishes a reusable RNA preparation platform applicable across swine, human, or other mammalian whole blood studies in host-pathogen research.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by capturing both coding and non-coding RNA layers from identical biological samples.
• Operational Value: Increases throughput and reduces reagent consumption by enabling dual-library generation from a single extraction.
• Strategic Value: Improves go/no-go decisions by providing multi-layered transcriptomic context that reduces false positives in target validation.
• Portfolio Impact: Supports risk-adjusted advancement by identifying whether expression changes are driven by direct transcriptional effects or ncRNA-mediated regulation.

Implementation Considerations

• Requires expertise in RNA handling, phenol-chloroform extraction, and RNase inhibition to prevent degradation.
• Depends on access to thermal cyclers, centrifuges capable of 10,000×G, and biological safety cabinets for BSL-2 compliance.
• Necessitates standardization of globin reduction oligo concentrations and hybridization timing across users and sites.
• Adaptation to other species may require validation of globin reduction efficacy and RNA integrity metrics.
• Practical limitation: Hazardous reagents (acid phenol chloroform) mandate fume hood use and PPE, increasing procedural complexity.

Biopharma FAQs